According to reports from Business Standard, Biogen Pharmachem Industries reported a standalone net profit of ₹1.00 crore in the quarter ended March 2026, marking a complete turnaround from the net loss of ₹0.36 crore recorded during the corresponding quarter of the previous year ended March 2025. The company's financial performance showed a dramatic reversal in profitability during the quarter, with the latest results announced on May 14, 2026 at the company's board meeting.
As reported by Business Standard, the company reported zero sales for both the quarter ended March 2026 and the corresponding quarter of the previous year ended March 2025. However, the latest results from Univest indicate that Biogen Pharmachem Industries achieved revenue of approximately ₹15 crore in Q4 FY26, representing a significant improvement in revenue generation compared to the previous year. The company manufactures active pharmaceutical ingredients and pharmaceutical formulations for domestic and international markets.
According to Business Standard, for the full financial year ended March 2026, the company reported a net profit of ₹0.86 crore compared to a net loss of ₹0.29 crore during the previous year ended March 2025. The company maintained zero sales throughout both the current and previous financial years, as reported by Business Standard. The latest results demonstrate the company's operational performance during the January to March 2026 quarter, positioning it for potential growth in the upcoming financial year.
